Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs

REFERENCES

1. 1.↵
   1. Chandran V,
   2. Raychaudhuri SP

   . Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010;34:314–21.

   OpenUrlCrossRef
2. 2.↵
   1. Ibrahim G,
   2. Waxman R,
   3. Helliwell PS

   . The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 2009;61:1373–8.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. McHugh NJ,
   2. Balachrishnan C,
   3. Jones SM

   . Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 2003;42:778–83.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Gordon GB,
   2. Ruderman E

   1. Gladman DD

   . Disability and quality of life considerations. Psoriatic arthritis. In: Gordon GB, Ruderman E, eds. Psoriasis and psoriatic arthritis: an integral approach. Heidelberg: Springer-Verlag; 2005:118–237.
5. 5.↵
   1. Helliwell P,
   2. Coates L,
   3. Chandran V,
   4. Gladman D,
   5. de Wit M,
   6. FitzGerald O,
   7. et al.

   Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res 2014;66:1759–66.

   OpenUrlCrossRef
6. 6.↵
   1. Ash Z,
   2. Gaujoux-Viala C,
   3. Gossec L,
   4. Hensor EM,
   5. FitzGerald O,
   6. Winthrop K,
   7. et al.

   A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71:319–26.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Glintborg B,
   2. Østergaard M,
   3. Dreyer L,
   4. Krogh NS,
   5. Tarp U,
   6. Hansen MS,
   7. et al.

   Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti–tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011;63:382–90.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Coates LC,
   2. Fransen J,
   3. Helliwell PS

   . Defining disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69:48–53.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Coates L,
   2. Helliwell P

   . Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res 2010;62:965–9.

   OpenUrlCrossRef
10. 10.↵
    1. Coates LC,
    2. Cook R,
    3. Lee KA,
    4. Chandran V,
    5. Gladman DD

    . Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res 2010;62:970–6.

    OpenUrlCrossRef
11. 11.↵
    1. Haddad A,
    2. Thavaneswaran A,
    3. Ruiz-Arruza I,
    4. Pellett F,
    5. Chandran V,
    6. Cook RJ,
    7. et al.

    Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis. Arthritis Care Res 2015;67:842–7.

    OpenUrlCrossRef
12. 12.↵
    1. Helliwell PS,
    2. FitzGerald O,
    3. Fransen J,
    4. Gladman DD,
    5. Kreuger GG,
    6. Callis-Duffin K,
    7. et al.

    The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013;72:986–91.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Nell-Duxneuner VP,
    2. Stamm TA,
    3. Machold KP,
    4. Pflugbeil S,
    5. Aletaha D,
    6. Smolen JS

    . Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis 2010;69:546–9.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Taylor W,
    2. Gladman D,
    3. Helliwell P,
    4. Marchesoni A,
    5. Mease P,
    6. Mielants H;
    7. CASPAR Study Group

    . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Ritchlin CT,
    2. Kavanaugh A,
    3. Gladman DD,
    4. Mease PJ,
    5. Helliwell P,
    6. Boehncke WH,
    7. et al;
    8. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

    . Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387–94.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Lubrano E,
    2. Spadaro A,
    3. Marchesoni A,
    4. Olivieri I,
    5. Scarpa R,
    6. D’Angelo S,
    7. et al.

    The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Clin Exp Rheumatol 2011;29:80–4.

    OpenUrlPubMed
17. 17.↵
    1. Heuft-Dorenbosch L,
    2. Spoorenberg A,
    3. van Tubergen A,
    4. Landewé R,
    5. van ver Tempel H,
    6. Mielants H,
    7. et al.

    Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127–32.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Chandran V,
    2. Gottlieb A,
    3. Cook RJ,
    4. Duffin KC,
    5. Garg A,
    6. Helliwell P,
    7. et al.

    International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails and dactylitis. Arthritis Rheum 2009;61:1235–42.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Ranza R,
    2. Marchesoni A,
    3. Calori G,
    4. Bianchi G,
    5. Braga M,
    6. Canazza S,
    7. et al.

    The Italian version of the Functional Disability Index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol 1993;11:123–8.

    OpenUrlPubMed
20. 20.↵
    1. Cauli A,
    2. Gladman DD,
    3. Mathieu A,
    4. Olivieri I,
    5. Porru G,
    6. Tak PP,
    7. et al.

    Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol 2011;38:898–903.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Fransen J,
    2. van Riel PL

    . The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005;23:S93–9.

    OpenUrlPubMed
22. 22.↵
    1. Husic R,
    2. Gretler J,
    3. Felber A,
    4. Graninger WB,
    5. Duftner C,
    6. Hermann J,
    7. et al.

    Disparity between ultrasound and clinical findings in psoriatic arthritis. Ann Rheum Dis 2014;73:1529–36.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Shammas RM,
    2. Ranganath VK,
    3. Paulus HE

    . Remission in rheumatoid arthritis. Curr Rheumatol Rep 2010;12:355–62.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Ma MH,
    2. Scott IC,
    3. Kingsley GH,
    4. Scott DL

    . Remission in early rheumatoid arthritis. J Rheumatol 2010;37:1444–53.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Lubrano E,
    2. Perrotta FM,
    3. Marchesoni A,
    4. D’Angelo S,
    5. Ramonda R,
    6. Addimanda O,
    7. et al.

    Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study. J Rheumatol 2015;42:258–63.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Spadaro A,
    2. Lubrano E,
    3. Marchesoni A,
    4. D’Angelo S,
    5. Ramonda R,
    6. Addimanda O,
    7. et al.

    Remission in ankylosing spondylitis treated with anti-TNF-a drugs: a national multicentre study. Rheumatology 2013;52:1914–9.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. Mease PJ,
    2. Heckaman M,
    3. Kary S,
    4. Kupper H

    . Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT. J Rheumatol 2013;40:647–52.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    1. Costa L,
    2. Caso F,
    3. Ramonda R,
    4. Del Puente A,
    5. Cantarini L,
    6. Darda MA,
    7. et al.

    Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res 2015;61:147–53.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Vastesaeger N,
    2. van der Heijde D,
    3. Inman RD,
    4. Wang Y,
    5. Deodhar A,
    6. Hsu B,
    7. et al.

    Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 2011;70:973–81.

    OpenUrlAbstract/FREE Full Text
30. 30.↵
    1. Perrotta FM,
    2. Addimanda O,
    3. Ramonda R,
    4. D’Angelo S,
    5. Lubrano E,
    6. Marchesoni A,
    7. et al.

    Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFa drugs. Reumatismo 2014;66:208–14.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Theander E,
    2. Husmark T,
    3. Alenius GM,
    4. Larsson PT,
    5. Teleman A,
    6. Geijer M,
    7. et al.

    Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis 2014;73:407–13.

    OpenUrlAbstract/FREE Full Text
32. 32.↵
    1. Salaffi F,
    2. Ciapetti A,
    3. Carotti M,
    4. Gasparini S,
    5. Gutierrez M

    . Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world. Biomed Res Int 2014;2014:528105.

    OpenUrlPubMed